Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925938 | 0.82 | AOC3 (0.35) | GBA1PIK3CAHCAR3 | |
| SCHEMBL830188 | 0.82 | NOS3 (0.33) | GBA1 | |
| SCHEMBL9925952 | 0.79 | GBA1 (0.48) | GBA1HCAR3 | |
| SCHEMBL17161196 | 0.79 | POLB (0.33) | CKS1BSKP1SKP2KCNH2 | |
| SCHEMBL24721127 | 0.76 | POLB (0.33) | — | |
| SCHEMBL19309162 | 0.76 | KCNH2 (0.44) | KCNH2 | |
| Dimethylamine SCHEMBL9222538 | 0.74 | NOS3 (0.30) | — | |
| SCHEMBL12693739 | 0.73 | DGAT1 (0.36) | HCAR3 | |
| SCHEMBL10280986 | 0.70 | — | — | |
| SCHEMBL46324 | 0.70 | MEN1 (0.37) | CKS1BSKP1SKP2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | CKS1B 460/4885SKP1 150/4885SKP2 360/4885 |
| US-20160207940-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CKS1B 529/4885SKP1 780/4885SKP2 1065/4885 |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | CKS1B 556/4885SKP1 716/4885SKP2 57/4885 |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | CKS1B 1807/4885SKP1 1689/4885SKP2 3797/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | CKS1B 382/4885SKP1 1348/4885SKP2 612/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | CKS1B 556/4885SKP1 716/4885SKP2 57/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CKS1B 87/4885SKP1 720/4885SKP2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.